Navigation Links
Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Date:1/6/2009

RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.

"The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations," said Dr. George Painter, Chimerix President and CEO. "We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus."

The Phase I study of CMX001 was a blinded, randomized, placebo-controlled study that evaluated the safety and pharmacokinetics of orally administered CMX001 in healthy volunteers. The study found CMX001 to be well tolerated at all doses in 84 healthy volunteers.

The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria, a condition which may eventually lead to loss of the kidney graft, or to uncontrolled bleeding in the bladder. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease, a viral disease that may lead to blindness or severe gastrointestinal disease after bone marrow transplant.

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug to treat smallpox infection is needed to help people who become ill after exposure to the disease or those who cannot be vaccinated. The work is partially funded by a $36.1 million grant
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Carrington Completes $8 Million Financing
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. New Brunswick Scientific Completes Merger Transaction with Eppendorf
9. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
10. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
11. Optherion, Inc. Completes $37 Million Start Up Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /PRNewswire/ - SQI Diagnostics ... announced that, as a result of recent discussions with ... common shares of the Company, after dealing with certain ... and special meeting of shareholders on March 26, 2015 ... that the election of directors will take place when ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... March 10, 2015 Transforming How ... "Personalized Medicine in Human Space Flight" by ... J. Goodwin , Ph.D. was recently featured by Springer ... two years. Specifically, "Personalized Medicine in Human ... papers published in 2013 and 2014 from Springer in ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... STM publisher Springer and Beijing Normal University Press ... Governance Project Series. The agreements for the first seven ... CEO Springer Science+Business Media, and Prof. Geng Yang, CEO ... The Integrated Risk Governance Project (IRG-Project) is supported by ...
... East region is expecting a demographic explosion in the number of ... 2020 it is expected that 25% of the population will be ... to 40%. This is a warning call for health ... a dramatic rise in age-related chronic diseases such as osteoporosis. ...
... LA JOLLA, CA May 10, 2012 Scientists at ... that act to block an enzyme that has been linked ... as some inflammation-promoted cancers. The new study, published ... new compounds that inhibit an important enzyme called PRMT1 (protein ...
Cached Biology News:Springer and the Beijing Normal University Press sign agreement on new book series 2New screening technique yields elusive compounds to block immune-regulating enzyme 2New screening technique yields elusive compounds to block immune-regulating enzyme 3
... Extraction Reagent extracts cytosolic proteins ... while preserving their phosphorylation state. ... the CytoBuster Protein Extraction reagent, ... is compatible with Western blotting, ...
... to WinList come straight from the folks ... like automatic region positioning, N-Stat regions, and ... suggestions, thoughtful conversations, and careful design. Of ... on are still there, too. WinList leads ...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
AK6 Antibody...
Biology Products: